The Steyri iodized kesha alcohol injection was approved for sale.

Introduction: The drug registration of this drug is classified as Chemical Class 4 and is considered to be evaluated through the consistent evaluation of the quality and efficacy of generic drugs.
25, Staly announced that its wholly-owned subsidiary, Shanghai Staili Pharmaceutical Co., Ltd., had recently received approval from the State Drug Administration to issue the "Drug Registration Approval" for iodized salmanol injections.
drug registration of this drug is classified as Chemical Class 4 and is considered to be evaluated through the consistent evaluation of the quality and efficacy of generic drugs.
iodized kesal injection adaptation includes cardiovascular angiitis, cerebrovascular angiology, exoskeleton angiosis, abdominal angiosis, urinary tract angiitis, intravenous angiology and CT enhancement examination.
iodized keshadol, developed by Nycomed, Norway, belongs to a non-ionic type of iso-permeable djubo contrast agent, good water solubility, and plasma and other seepage, permeable pressure toxicity is lower than low seepage contrast agent.
iodized kesal was approved for listing by the U.S. FDA in 1996 and was listed in China in 2001 under the trade name Visipaque and the English name Iodixanol Injection.
is an X-ray non-ionic iodine spectronic agent, similar varieties include iodized sea alcohol, iodized parol, iodized prosamine, iodine mepple and so on.
, six companies in China are selling iodized kesha alcohol preparations, of which about 90% of the market share is held by Jiangsu Hengrui Pharmaceutical Co., Ltd. and GE Healthcare AS.
according to data from the Newportpremium database and the China Pharmaceutical Industry Information Center, the global market for iodized salmanol in 2018 was $574 million, up 17.62% year-on-year and growing at an all-time high.
is consistent with the market pattern of iodine sea alcohol and iodized parol, iodized kesha alcohol in Europe and the United States accounted for the highest proportion of the scale.
2019, the domestic market size of iodized kesha alcohol was approximately 4,971 million yuan, an increase of 38.43% year-on-year.
Iodoxal is currently the largest imager product in the domestic market with a market share of 35.65% in 2019, while X-ray spectrtics account for the highest share of the entire domestic spectrallycant market.
.